Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome
The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Newark Beth Israel Medical Center.
Recruitment status was  Recruiting
Study NCT01170338   Information provided by Newark Beth Israel Medical Center

First Received on July 26, 2010.   No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Smoking
Acute Coronary Syndrome
More general conditions related to this trial
Angina Pectoris
Cardiovascular Diseases
Chest Pain
Habits
Heart Diseases
Myocardial Ischemia
Pain
Signs and Symptoms
Vascular Diseases
Interventions listed in this trial
control
Additional drug interventions recognized in this trial
Varenicline
More general drug interventions related to this trial
Cholinergic Agents
Cholinergic Agonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nicotinic Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Newark Beth Israel Medical Center


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services